0001645113-26-000017
SEC filingRevenue grew 8% to $655.4M, driven by international growth and reimbursement improvements, while net loss improved to $136.2M.
NovoCure is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells. The therapy is delivered through medical devices, with commercial products Optune Gio (for glioblastoma), Optune Lua (for non-small cell lung cancer and malignant pleural mesothelioma), and Optune Pax (for pancreatic cancer). The company focuses on driving adoption of these products and obtaining regulatory approval for new indications.
The Business section does not disclose formal reporting segments. The company organizes its operations by therapeutic areas: central nervous system indications (GBM, brain metastases) and torso indications (NSCLC, pancreatic cancer, MPM). However, no financial segment information is provided.
Key commercial products include Optune Gio (approved for newly diagnosed and recurrent GBM in multiple countries), Optune Lua (approved for metastatic NSCLC and MPM in the U.S., EU, and Japan), and Optune Pax (approved for locally advanced pancreatic cancer in the U.S. as of February 2026). A PMA application has been submitted for brain metastases from NSCLC under the proposed brand Optune Mya. The TTFields platform is delivered via a portable electric field generator and arrays. Preclinical research tools include inovitro and inovivo systems.
The company markets directly to patients after prescription, except in countries like Japan where distribution is through hospitals. As of December 31, 2025, NovoCure had 217 sales force colleagues globally. Reimbursement is sought from public and private payers; Optune Gio has national reimbursement in several countries, while Optune Lua and Optune Pax do not yet have national reimbursement. No individual customer concentration is disclosed.
The market for cancer treatments is intensely competitive. NovoCure faces competition from companies developing other anti-cancer therapies for GBM, NSCLC, pancreatic cancer, and MPM. The company is aware of third parties in the U.S. and China developing TTFields-like devices. Although some early patents have expired, competitors must still conduct clinical studies and obtain regulatory approvals, and NovoCure continues to expand its intellectual property portfolio.
NovoCure's key priorities include driving commercial adoption of its three commercial devices, obtaining regulatory approval for new indications (e.g., brain metastases from NSCLC via Optune Mya), advancing clinical and product development programs to extend survival in aggressive cancers, and expanding access to TTFields therapy in additional geographic markets while securing reimbursement.
As of December 31, 2025, NovoCure employed 1,605 people (up from 1,488 in 2024), including 217 sales force colleagues. The company emphasizes recruiting and retaining sales, marketing, patient support, and R&D personnel to support growth.
NovoCure's net revenues increased 8% to $655.4M in FY2025, up from $605.2M in FY2024. The growth was primarily driven by international markets: France (+$20.5M), Germany (+$14.1M), and other international markets (+$21.7M), partly benefiting from $10.9M in exchange rate effects. US revenue declined $6.2M due to reduced one-time benefits from prior period claims. Recognized Optune Lua revenue totaled $10.4M ($5.8M NSCLC, $4.6M MPM). Gross profit grew 4.4% to $488.5M, but gross margin contracted from 77% to 75% due to higher tariffs, array costs from a new array rollout, NSCLC launch costs, and a $3.2M inventory obsolescence provision for Optune Lua arrays. Operating loss improved to $153.8M from $170.5M, driven by lower share-based compensation ($104.8M vs $160.0M) and a 6% reduction in G&A expenses. Net loss narrowed to $136.2M from $168.6M, aided by a $37.5M swing in income tax expense (benefit of $0.023M vs expense of $37.5M) due to one-time tax adjustments and favorable law changes. Adjusted EBITDA turned negative to $34.3M from positive $0.8M, reflecting increased investment in NSCLC launch and pre-launch activities for new indications.
NovoCure operates as a single segment. Revenue growth was driven by active patient expansion in international markets. Active patients on Optune Gio grew 9% to 4,464, while Optune Lua patients more than tripled to 156. International active patients increased 17% to 2,259, outpacing US growth of 8% to 2,361. Prescriptions received rose 9% to 7,035, with international prescriptions up 8% and US up 9%. The international mix continues to increase, with France and Germany showing strong momentum. Cost of revenues per active patient per month (ex-Zai) rose to $2,950 from $2,683, driven by tariffs, array costs, and launch-related expenses.
Management provided no quantitative guidance but outlined strategic priorities: drive commercial adoption of Optune Gio, Optune Lua, and Optune Pax; obtain regulatory approvals for new indications such as brain metastases from NSCLC (following positive METIS data); and advance clinical trials (TRIDENT, KEYNOTE D58, LUNAR-2, PANOVA-4). The company expects continued increases in R&D, sales & marketing, and G&A expenses over the next several years, potentially outpacing gross profit growth. NovoCure believes its $447.7M in cash and short-term investments is sufficient for at least 12 months. The company is actively mitigating tariff risks by onboarding new suppliers in Mexico and Ireland. The repayment of the $560.9M convertible note in November 2025 was partially offset by drawing $100M from the Tranche B loan, and the remaining Tranche C and D options were not exercised. The company's focus remains on positioning for future profitability through strategic investments and supply chain optimization.
As of December 31, 2025, total assets were $804.3M, down from $1,240.8M in 2024. Cash and cash equivalents were $93.5M (2024: $163.8M), and short-term investments were $354.1M (2024: $796.1M), reflecting deployment of funds for debt repayment and operations. Total debt decreased to $195.0M (net carrying) from $655.5M, driven by the full repayment of the $560.9M convertible notes in November 2025 and $200M drawn on the senior secured credit facility. Shareholders' equity was $340.5M, down slightly from $360.2M due to net losses. Inventory increased to $41.1M from $35.1M, and deferred revenue (short-term contract liabilities) stood at $15.9M.
Purchase obligations amounted to $38.9M as of December 31, 2025, with no further breakdown by timing. Operating lease commitments total $62.7M in future minimum lease payments, with $12.1M due in 2026. The Zai License Agreement also includes potential milestone payments of up to $78M, though none were included in the transaction price as of year-end.
The company did not repurchase shares or pay dividends during the year. The major capital allocation event was the refinancing of the convertible notes: $560.9M repaid at maturity, partially funded by $200M drawn on the senior secured credit facility (Tranche A and B). No new buyback authorization or dividend was announced. Capital expenditures are not separately disclosed in the notes; however, cash flow from investing activities shows $26.6M in purchases of property, equipment, and field equipment.
NovoCure operates as a single reportable segment: the TTFields segment. Revenue is derived from monthly treatments and recognized over time. Geographic revenue split (by patient location) for 2025: United States $385.6M (58.8%), Germany $79.4M (12.1%), France $76.2M (11.6%), Japan $37.8M (5.8%), Other international $56.9M (8.7%), and Greater China $19.4M (3.0%). This mix is consistent with prior period patterns.
NovoCure operates in highly regulated markets (FDA, EU MDR, Japan PMDA). The transition to MDR and UK regulations may delay certifications. Post-market modifications require new approvals, risking product recalls or marketing suspension. Geopolitical risks include Israeli operations due to regional instability, affecting R&D and supply chain.
Reimbursement is a critical risk. Medicare coverage is limited for Optune Gio, and broader coverage for new indications (NSCLC, pancreatic) is uncertain. Private payer denial and international reimbursement variability could significantly reduce revenue. Absence of specific CPT codes for physician services may deter adoption.
Heavy dependence on Optune Gio for GBM; future revenue hinges on approvals for NSCLC, MPM, and pancreatic cancer. Clinical trial outcomes are unpredictable; patient enrollment, adverse events, or protocol changes can cause delays. Even with approvals, market acceptance is not guaranteed due to device burden (shaving, continuous wear) and physician reluctance.
Single-source suppliers for key components pose a high risk. Any disruption could halt production for extended periods. Quality control failures could lead to regulatory action or product recalls. Third-party manufacturers must comply with QSR; noncompliance could interrupt supply.
NovoCure has a history of operating losses and expects to continue incurring substantial costs. The $200M senior secured credit facility imposes restrictive covenants, limiting operational flexibility. Interest rate fluctuations could increase debt service costs. Additional capital may be needed but may not be available on favorable terms.
The oncology market is intensely competitive with large, well-capitalized players. Alternative therapies could surpass TTFields. Patent expirations (2025-2041) may erode competitive advantage. Litigation over IP could divert resources and result in loss of market exclusivity.
Growth may strain management and systems. Key employee retention is critical; competition for talent is intense. Cybersecurity threats are increasing; a breach could disrupt operations or compromise patient data, leading to liabilities and reputational damage.
The provided document excerpt does not contain the actual cash flow statement figures. Only audit reports were included.